What Insulet's FY2025 10-K says: 12 signals
Insulet filed its latest 10-K with the SEC on Feb 18, 2026. It discusses capex increase, automation investment and capacity constraint.
Public (PODD)Medical Equipment Manufacturing1,001 to 5,000 employeesinsulet.comLinkedIn
- Filed
- Feb 18, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 8
What Insulet's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Canceled Omnipod GO commercialization, resulting in a $13.5M inventory write-off.
A strategic pivot away from the Omnipod GO product led to a $13.5 million charge for unusable inventory.
$13.5M
Charge for unusable inventory components for the discontinued Omnipod GO product
Launched "Omnipod Discover" data analytics and reporting platform in 2026.
The company launched a new data platform to provide actionable insights to users and healthcare providers.
data analyticscloudGlooko Inc.
Investing in a new manufacturing plant in Costa Rica to support future growth
Following the start of production at its new Malaysia plant in 2024, Insulet is already investing in another facility in Costa Rica.
International revenue surged 44.1% to $754.3M, driven by Omnipod 5 launches
The company experienced rapid international revenue growth of 44.1% (39.3% in constant currency) in 2025, primarily due to the successful launch of Omnipod 5 in new markets.
$754.3M
International revenue for 2025
44.1%
Year-over-year international revenue growth
Expanded into 9 new countries in 2025 and the Middle East in early 2026
Insulet is aggressively expanding its global footprint, launching Omnipod 5 in nine new countries in 2025 and several Middle Eastern countries in early 2026, bringing the total to 19 countries.
R&D spending increased 37.1% to $301.1M to develop next-gen products and integrations
The company boosted R&D expenses by $81.5 million in 2025, a 37.1% increase, to fund development of its pipeline.
$301.1M
Total R&D expense for 2025
37.1%
Year-over-year increase in R&D spending
fully closed loop AID systemAIDAbbott
Expanding Omnipod 5 integrations with Dexcom G7 and Abbott Libre 2 Plus sensors.
The company's core product strategy relies on successful integration with third-party CGM sensors from Dexcom and Abbott.
BluetoothDexcom, Inc.Abbott Diabetes Care, Inc.
Three distributors account for 78% of total revenue in 2025
Insulet has a high revenue concentration with three distributors representing 27%, 26%, and 25% of total revenue.
78%
Revenue from top 3 distributors (27% + 26% + 25%)
Showing 8 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Insulet with the Signal API
One POST /v1/companies/enrich call with insulet.com returns Insulet 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"insulet.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Insulet 10-K
When did Insulet file its latest 10-K?
What does Insulet's latest 10-K say about inventory issue?
Where can I find Insulet's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .